Kinnevik Boston Consulting Group Matrix

Pleo, a digital corporate finance management solution provider, demonstrated robust expansion in 2024. The company saw its group revenue climb by 37%, with a particularly strong 56% surge in SaaS revenue. This performance positions Pleo as a significant growth driver within Kinnevik's portfolio.

With around 40,000 active users across Europe, Pleo has cemented a solid market presence. Its success in the expanding software sector underscores its potential, making it a prime candidate for continued strategic investment by Kinnevik.

Stars in the Kinnevik BCG Matrix represent high-growth, high-market-share businesses. These are typically companies that are leaders in rapidly expanding industries and are generating significant revenue growth. Kinnevik's strategy involves investing heavily in these businesses to maintain their market position and capitalize on future growth opportunities.

Mews, a cloud-native property management system, exemplifies a Star. It achieved unicorn status in 2024 and saw revenue growth of 50% to over EUR 200 million in the same year. Further bolstering its position, Mews secured EUR 70 million in funding in early 2025, signaling continued strong investor confidence and market leadership.

Kinnevik's robust net cash position, standing at SEK 10.9 billion at the close of 2024 and SEK 9.6 billion by the end of Q2 2025, highlights its strategic advantage. This substantial liquidity, bolstered by successful past investments and divestments, means the company has considerable flexibility in how it deploys capital.

This strong cash balance allows Kinnevik to operate as a 'cash cow,' generating the necessary funds to nurture and launch new ventures with high growth potential. The limited need for further investment in its established portfolio frees up resources for these strategic growth initiatives.

Cash cows within Kinnevik's portfolio represent established businesses generating consistent, strong profits with minimal reinvestment needs. These entities provide a stable source of cash flow that can be strategically deployed to fund other ventures or returned to shareholders. Kinnevik's divestment of Tele2 in 2024, yielding SEK 13 billion, exemplifies a successful realization of cash from a mature asset, effectively acting as a cash cow for the group.

The company's focus on nurturing its existing profitable businesses, such as those achieving positive EBITDA in 2024 and early 2025, reinforces this strategy. These mature operations require less capital, allowing Kinnevik to leverage their earnings for growth initiatives elsewhere.

Kinnevik's robust net cash position of SEK 10.9 billion at the end of 2024 and SEK 9.6 billion by Q2 2025 underscores its capacity to operate as a cash cow, funding new opportunities from its strong liquidity base.

The transition of companies like Spring Health and TravelPerk from high-growth 'Stars' to potential future cash cows is a key element of Kinnevik's long-term strategy, aiming for stable income generation through dividends or profitable exits.

Sure, Lunar, and XYB, having been divested by Kinnevik in Q1 2025, likely represent the Dogs in their BCG Matrix. Kinnevik's strategic repositioning away from these financial services investments, as evidenced by their capital release, indicates these entities were not meeting the company's growth objectives or strategic fit within its digital consumer focus. This move aligns with the characteristic of Dogs, which typically exhibit low market share and low growth potential, prompting companies to divest them.

Kinnevik's portfolio includes several companies that fit the 'Dog' category in the BCG Matrix, characterized by low market share and low growth prospects. These are typically assets that Kinnevik strategically exits or restructures due to underperformance. For instance, Tele2 was divested in 2024, and VillageMD was fully written down the same year, both indicating they were considered Dogs.

Companies like Lunar and XYB were divested in Q1 2025, also aligning with the 'Dog' profile due to not meeting Kinnevik's growth objectives. MatHem, despite ongoing reconstruction efforts approved in July 2025, remains in the 'Dog' quadrant due to its weak market position and financial strain.

Global Fashion Group (GFG) experienced Net Asset Value (NAV) pressure in H1 2024, signaling potential underperformance and placing it under strategic review for its future within Kinnevik's portfolio.

Kinnevik's recent SEK 335 million investment in a new techbio company during the first half of 2025 places this venture squarely in the Question Mark category of the BCG matrix. This significant capital injection into a high-growth sector highlights Kinnevik's strategic intent to capture market share in a nascent area for the company.

Given its current limited market presence in techbio, the company will demand substantial ongoing investment and strategic guidance to evolve. The success of this Question Mark will hinge on Kinnevik's ability to nurture its growth and potentially transform it into a Star or Cash Cow in the future.

Question Marks represent investments in high-growth markets where the company has a low market share. These ventures require significant capital to grow, and their future success is uncertain, meaning they could become Stars or Dogs.

Kinnevik's 2025 investment in a new techbio company for SEK 335 million exemplifies a Question Mark, aiming to capture market share in a nascent but high-growth sector.

Similarly, Tandem Health, a medical AI scribe company, is a 2025 addition to Kinnevik's portfolio, positioned as a Question Mark due to its early stage and uncertain market share in the growing healthcare infrastructure market.

Enveda, a biotech firm using AI for drug discovery, is also a Question Mark, showing rapid expansion potential with ongoing clinical trials but a minimal market share in a competitive sector, necessitating substantial capital.